Nexstim Selected as a 2014 Red Herring Top 100 Europe

Helsinki, Finland, April 19, 2014 --(PR.com)-- Red Herring’s Top 100 Europe celebrates the exceptional accomplishments of technology companies and their position to grow at an explosive rate. The awards winners were announced today, and Nexstim has proudly been selected in this prestigious group as a Top 100 Europe.

“I’m very excited about this award and recognition of our work to get help for patients with this remarkable technology we have developed” said Janne Huhtala, CEO of Nexstim. “I am honored to work with Nexstim’s very skillful people who have made this happen.”

Since 1996, the Red Herring 100 winners have been recognizing the most exciting startups from around the globe. Nexstim is honored to join this mark of distinction, which identifies promising new companies. They join a long list of outstanding companies such as Facebook, Twitter, Google, Yahoo, Skype, Salesforce.com, YouTube, and eBay.

“Selecting startups that show the most potential for disruption and growth is never easy,” said Alex Vieux, publisher and CEO of Red Herring. “We looked at hundreds and hundreds of candidates from all across the continent, and after much though and debate, narrowed the list down to the Top 100 Winners. Each year, the competition gets tougher but we believe Nexstim demonstrates the vision, drive and innovation that define a Red Herring Winner.”

Red Herrings editorial team makes their selection through an evaluation of both quantitative and qualitative criteria, such as level of specialty, social contribution, international footprint, growth rate, and technological advantages. The executive team assesses a company’s track record and industry standing in the same industry sector, making the list a valuable instrument of discovery and advocacy for the most promising new businesses in Europe.

About Nexstim:
Founded in 2000, Finland-based Nexstim is the world leader in image-guided transcranial magnetic stimulation (TMS). The company is committed to improving the quality of life of patients with significant unmet clinical needs. Nexstim has pioneered the technology for brain diagnostics with the first and only FDA-cleared and CE-marked navigated TMS device for pre-surgical mapping. The advanced technology providing navigation to TMS (nTMS) has led NBS to be recognized as the emerging standard for pre-operative direct functional mapping.

Nexstim’s technology has also been proven to enable treatment of brain injury and disease using repetitive TMS (rTMS) with accurate and repeatable 3D-guidance of therapeutic electrical field. Initially being studied as an adjunct to physiotherapy in stroke rehabilitation, Nexstim’s Navigated Brain Therapy (NBT) System enable personalized, and non-drug treatment.

Caution: Nexstim’s NBS System is cleared by the FDA for assessment of the motor and speech cortices for pre-procedural planning. The NBT System is not cleared for commercial distribution in the United States. www.nexstim.com